Autophagy as a Possible Mechanism of Resistance in pNET Treatment Abstract #1111

Introduction: Pancreatic neuroendocrine tumor (pNET) patients often display primary or secondary resistance to Sunitinib, an anti-angiogenic multi-receptor tyrosine kinase inhibitor which has been approved for the treatment of late stage pNETs. In late cancer stage autophagy often has a tumor promoting role. Sunitinib might additionally activate autophagy through inhibition of mTOR or induction of hypoxia.
Aim(s): To assess whether autophagy acts as a mechanism of resistance in late stage pNETs and if autophagy inhibition increases therapy efficacy
Materials and methods:
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Tabea Wiedmer

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1638 3D Primary Cell Culture: A New Promising Preclinical Model for Pancreatic Neuro-Endocrine Tumors (pNETs).
Introduction: The lack of adequate in vitro and in vivo preclinical models has hampered the identification of novel treatment options and the development of personalized therapy selection for pNET patients.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Ilaria Marinoni
#1312 Epigenetic Remodeling upon DAXX and ATRX Loss in Pancreatic Neuro-endocrine tumors (pNETs)
Introduction: DAXX and or ATRX loss occur in 40% of sporadic pNETs. DAXX and ATRX participate in the cell epigenetic status maintenance. Epigenetic changes influence gene expression, function of telomeres and genomic stability. We hypothesize that DAXX/ATRX loss drives tumor progression in pNET through epigenetic changes affecting genomic stability.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Ilaria Marinoni
Keywords: DAXX/ATRX, epigenetic, CIN
#1932 Radiological Changes in the Treatment of Pancreatic Neuroendocrine Tumors (PNET) with Sunitinib: RECIST vs CHOI Criteria. CRIPNET-GETNE Study
Introduction: In PNET, phase III studies with antitarget drugs show few responses based on RECIST criteria despite a significant impact on progression free survival (PFS). Antiangiogenic drugs show in other tumors that responses are not always associated with a reduction in tumor volume on CT.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Maria Pilar Solis-Hernandez
Keywords: sunitinib, PNET, choi, recist
#2235 Efficacy of Sunitinib Correlated with Clinical, Radiological Variables, Dose-Intensity and Treatment Time in Advanced Grade 1-2 Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study NCT02841865)
Introduction: Sunitinib has been shown to be effective in advanced pancreatic neuroendocrine tumors (PNETs) but it is not well known how dose-intensity and treatment time influence the results.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: PhD Paula Jimenez-Fonseca
#1247 Recist versus Choi Criteria Response Assesment in Patients with Advanced Pancreatic Neuroendocrine Tumor (PNET) Treated with Sunitinib
Introduction: Classically, the response assessment to systemic treatment is based on RECIST. In PNET treated with antiangiogenic targeted therapy as sunitinib there is no good correlation between response rate and progression free survival (PFS). Choi criteria might be an alternative to RECIST to evaluate the effect of sunitinib in patients with advanced PNET
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: PhD Paula Jiménez-Fonseca
Keywords: sunitinib, PNET, Choi, RECIST